The two Hep C drugs are similar enough chemically to warrant caution.
Gilead posted strong second-quarter earnings and is moving ahead aggressively with its new hepatitis C drugs.
Valuation shorts can be investment quicksand, explains TheStreet columnist Nate Sadeghi.
TheStreet contributor Nate Sadeghi calls for healthcare investors to start acting like owners.
With a second cancer drug approval looming, Onyx can join a select group of successful and profitable biotech companies.
TheStreet's Nathan Sadeghi-Nejad examines which health care stocks benefit from the Supreme Court's decision to uphold health care reform.
Advice to lorcaserin bulls: Cherish the moment but sell Arena, says TheStreet contributor Nate Sadeghi.
An undervalued stock could move higher if Alkermes continues to grow through acquisitions.
Six possible outcomes of the Court's healthcare ruling and what it means for healthcare stocks.
Contributor Nathan Sadeghi-Nejad offers tips to Glaxo's CEO on how to woo the stubborn HGSI into marriage.